



NEWS RELEASE

Media contacts:

Jessica Castles Smith
609.730.2160 office
732.501.8181 cell
jcastlsm@its.jnj.com

Christina Chan
908.927.5769 office
908.635.2406 cell
cchan20@its.jnj.com

Investor contacts:

Joseph J. Wolk
732.524.1142 office

Lesley Fishman
732.524.3922 office

Janssen Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for INVOKANA[®] (canagliflozin) to Reduce the Risk of Major Adverse Cardiovascular Events (MACE) Based on Landmark CANVAS Program

Filing includes data on the combined risk reduction of cardiovascular death, myocardial infarction and stroke in patients with type 2 diabetes

RARITAN, NJ, October 2, 2017 – Janssen Research & Development, LLC (Janssen) announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food & Drug Administration (FDA) seeking a new indication for INVOKANA[®] (canagliflozin) to reduce the risk of major adverse cardiovascular events (MACE), composed of cardiovascular (CV) death, myocardial infarction and stroke, in adults with type 2 diabetes who have established CV disease or are at risk for CV disease. The application also applies to INVOKANA[®]'s fixed-dose combinations, INVOKAMET[®] and INVOKAMET[®] XR, and is based on findings from the landmark CANVAS clinical trial program, which were presented at a special symposium at the American Diabetes Association 77th Scientific Sessions in June 2017 and simultaneously published in [The New England Journal of Medicine](#).¹

“People with type 2 diabetes have a substantially increased risk of developing cardiovascular disease, and it’s encouraging that we now have data to show INVOKANA[®] may help address this challenge,” said James F. List, M.D., Ph.D., Global Therapeutic Area Head, Cardiovascular & Metabolism, Janssen. “INVOKANA[®] has shown a clear benefit in reducing cardiovascular risk in adults with type 2 diabetes and we look forward to working with FDA as it reviews our filing.”

[Click to tweet:](#) .@JanssenUS submits sNDA to US #FDA for expanded INVOKANA[®] (canagliflozin) label. See full PI incl Boxed Warning <http://po.st/mQHTEI>

Of the approximately 30 million people living with diabetes in the United States, 90 to 95 percent have type 2 diabetes,² and are two to four times more likely to die from heart disease than those without diabetes.³

The sNDA is based on data from the CANVAS Program, which evaluated the CV safety and efficacy of canagliflozin relative to placebo in adults with type 2 diabetes who had either established CV disease or were at risk for CV disease, which was defined as having two or more CV risk factors. The primary endpoint was defined as MACE, composed of CV death, nonfatal myocardial infarction and nonfatal stroke. The CANVAS Program is composed of two similar clinical trials, CANVAS and CANVAS-R, and evaluated more than 10,000 patients for an average of 188 weeks, including 296 weeks in CANVAS and 108 weeks in CANVAS-R.

INVOKANA[®] was approved by the FDA on March 29, 2013 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

WHAT IS INVOKANA[®]?

INVOKANA[®] is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. INVOKANA[®] is not for people with type 1 diabetes or with diabetic ketoacidosis (increased ketones in blood or urine). It is not known if INVOKANA[®] is safe and effective in children under 18 years of age.

IMPORTANT SAFETY INFORMATION

INVOKANA[®] can cause important side effects, including:

- **Amputations.** INVOKANA[®] may increase your risk of lower-limb amputations. Amputations mainly involve removal of the toe or part of the foot; however, amputations involving the leg, below and above the knee, have also occurred. Some people had more than one amputation, some on both sides of the body. You may be at a higher risk of lower-limb amputation if you: have a history of amputation, have heart disease or are at risk for heart disease, have had blocked or narrowed blood vessels (usually in leg), have damage to the nerves (neuropathy) in the leg, or have had diabetic foot ulcers or sores. **Call your doctor right away if you have new pain or tenderness, any sores, ulcers, or infections in your leg or foot.** Your doctor may decide to stop your INVOKANA[®]. Talk to your doctor about proper foot care
- **Dehydration.** INVOKANA[®] can cause some people to become dehydrated (the loss of too much body water), which may cause you to feel dizzy, faint, lightheaded, or weak, especially when you stand up (orthostatic hypotension). You may be at higher risk of dehydration if you have low blood pressure, take medicines to lower your blood pressure (including diuretics [water pills]), are on a low sodium (salt) diet, have kidney problems, or are 65 years of age or older
- **Vaginal yeast infection.** Women who take INVOKANA[®] may get vaginal yeast infections. Symptoms include: vaginal odor, white or yellowish vaginal discharge (discharge may be lumpy or look like cottage cheese), or vaginal itching
- **Yeast infection of the penis (balanitis or balanoposthitis).** Men who take INVOKANA[®] may get a yeast infection of the skin around the penis. Symptoms include: redness, itching, or swelling of the penis; rash of the penis; foul-smelling discharge from the penis; or pain in the skin around penis

Talk to your doctor about what to do if you get symptoms of a yeast infection of the vagina or penis.

Do not take INVOKANA[®] if you:

- are allergic to canagliflozin or any of the ingredients in INVOKANA[®]. Symptoms of allergic reaction may include: rash; raised red patches on your skin (hives); or swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing
- have severe kidney problems or are on dialysis

Before you take INVOKANA[®], tell your doctor if you have a history of amputation; heart disease or are at risk for heart disease; blocked or narrowed blood vessels (usually in leg); damage to the nerves (neuropathy) of your leg; diabetic foot ulcers or sores; kidney problems; liver problems; history of urinary tract infections or problems with urination; are on a low sodium (salt) diet; are going to have surgery; are eating less due to illness, surgery, or change in diet; pancreas problems; drink alcohol very often (or drink a lot of alcohol in short-term); ever had an allergic reaction to INVOKANA[®]; or have other medical conditions.

Tell your doctor if you are or plan to become pregnant, are breastfeeding, or plan to breastfeed. INVOKANA[®] may harm your unborn baby. If you become pregnant while taking INVOKANA[®], tell your doctor right away. INVOKANA[®] may pass into your breast milk and may harm your baby. Do not breastfeed while taking INVOKANA[®].

Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Especially tell your doctor if you take diuretics (water pills), rifampin (used to treat or prevent tuberculosis), phenytoin or phenobarbital (used to control seizures), ritonavir (Norvir[®], Kaletra[®] – used to treat HIV infection), or digoxin (Lanoxin[®] – used to treat heart problems).

Possible Side Effects of INVOKANA[®]

INVOKANA[®] may cause serious side effects, including:

- **Ketoacidosis** (increased ketones in your blood or urine). **Ketoacidosis has happened in people who have type 1 or type 2 diabetes**, during treatment with INVOKANA[®]. Ketoacidosis is a serious condition, which may need to be treated in a hospital. Ketoacidosis may lead to death. **Ketoacidosis can happen with INVOKANA[®] even if your blood sugar is less than 250 mg/dL. Stop taking INVOKANA[®] and call your doctor right away if you get any of the following symptoms: nausea, vomiting, stomach-area pain, tiredness, or trouble breathing**
- **Kidney problems.** Sudden kidney injury has happened to people taking INVOKANA[®]. Talk to your doctor right away if you: 1) reduce the amount of food or liquid you drink, if you are sick, or cannot eat or 2) you start to lose liquids from your body from vomiting, diarrhea, or being in the sun too long
- **A high amount of potassium in your blood (hyperkalemia)**
- **Serious Urinary Tract Infections:** may lead to hospitalization and have happened in people taking INVOKANA[®]. Tell your doctor if you have signs or symptoms of a urinary tract infection such as: burning feeling while urinating, need to urinate often or right away, pain in the lower part of your stomach (pelvis), or blood in the urine. Some people may also have high fever, back pain, nausea, or vomiting
- **Low blood sugar (hypoglycemia).** If you take INVOKANA[®] with another medicine that can cause low blood sugar, such as a sulfonyleurea or insulin, your risk of getting low blood sugar is higher. The dose of your sulfonyleurea medicine or insulin may need to be lowered while you take INVOKANA[®]

Signs and symptoms of low blood sugar may include: headache, drowsiness, weakness, dizziness, confusion, irritability, hunger, fast heartbeat, sweating, shaking, or feeling jittery.

Serious allergic reaction. If you have any symptoms of a serious allergic reaction, stop taking INVOKANA[®] and call your doctor right away or go to the nearest hospital emergency room.

Broken Bones (fractures): Bone fractures have been seen in patients taking INVOKANA[®]. Talk to your doctor about factors that may increase your risk of bone fracture.

The most common side effects of INVOKANA[®] include: vaginal yeast infections and yeast infections of the penis; changes in urination, including urgent need to urinate more often, in larger amounts, or at night.

Tell your doctor if you have any side effect that bothers you or that does not go away. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Janssen Scientific Affairs, LLC at 1-800-526-7736.

Please see full [Product Information](#), including [Boxed Warning](#), and [Medication Guide](#) for INVOKANA[®].

Canagliflozin is licensed from Mitsubishi Tanabe Pharma Corporation.

Trademarks are those of their respective owners.

About the Janssen Pharmaceutical Companies

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us at [@JanssenUS](https://twitter.com/JanssenUS).

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the potential benefits and further development of canagliflozin. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Pharmaceuticals, Inc., any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2017, including under "Item 1A. Risk Factors," its most recently filed Quarterly Report on Form 10-Q, including under the caption "Cautionary Note Regarding Forward-Looking Statements," and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available

online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The Janssen Pharmaceutical Companies and Johnson & Johnson do not undertake to update any forward-looking statement as a result of new information or future events or developments.

¹ Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med*. 2017 Aug 17;377(7):644-657.

² Centers for Disease Control and Prevention. National diabetes statistic report, 2017: estimates of diabetes in the United States. Atlanta, GA: U.S. Department of Health & Human Services, Centers for Disease Control and Prevention, 2017. Available at: <https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf>. Accessed September 11, 2017.

³ American Heart Association. Cardiovascular Disease & Diabetes. American Heart Association, 2017. Available at: http://www.heart.org/HEARTORG/Conditions/More/Diabetes/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes_UCM_313865_Article.jsp#.WbawtvnyuUI. Accessed September 11, 2017.